Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insights Report 2023-2028: One of the Most Studied Immune Checkpoint After PD-1 and CTLA-4 - ResearchAndMarkets.com
Retrieved on:
Friday, March 17, 2023
The "Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
Key Points:
- The "Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
- LAG-3 is an immune checkpoint and has been considered as a target for developing drugs and therapies for the treatment of cancer, chronic infectious diseases, and autoimmune diseases.
- Future research also needs to focus on the effects of LAG-3 inhibition on other cells apart from the conventional T cells.
- Number Of LAG-3 Inhibitor Drugs In the Market: 1 Drug
Approved LAG-3 Inhibitor Drug Dosage, Patent & Pricing Insight
Number Of LAG-3 Inhibitor Drugs In Clinical Trials: > 35 Drugs
LAG-3 Inhibitor Drugs Clinical Trials Insight By Company, Country, Indication, & Phase